12:27 PM
 | 
Jul 12, 2018
 |  BC Extra  |  Financial News

Haitong leads Orig3n's series B

Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B round led by Haitong International. Orig3n did not disclose how much it raised in the initial close; however, it did say it has raised over $50 million since its founding, including a $12.5 million series A co-led by Hatteras Venture Partners and Syno Capital in 2015.

Orig3n is developing allogeneic cell therapies using a bank of "superdonor" cells that could be used to treat wide swaths of the population with little risk of rejection by the immune system (see "Superdonor Squad").

The company also has a platform to inexpensively produce induced pluripotent stem cells and differentiated cells that mimic clinical trial populations (see "Crowdsourcing Cells").

Hong Kong-based Haitong is also underwriting, along with Citi, the proposed IPO of microbiome company AOBiome Therapeutics Inc. (Cambridge, Mass.) on Hong Kong Exchanges and Clearing Ltd. (HKEX) (see "Stealth, AOBiome Propose Hong Kong Offerings").

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD